As Quidel Corp (QDEL) Share Price Declined, Shareholder Oracle Investment Management INC Decreased Stake by $6.98 Million

Investors sentiment decreased to 1.15 in Q2 2019. Its down 0.27, from 1.42 in 2019Q1. It is negative, as 22 investors sold QDEL shares while 43 reduced holdings. 20 funds opened positions while 55 raised stakes. 36.17 million shares or 2.10% more from 35.42 million shares in 2019Q1 were reported. 4,008 are held by M&T Bancshares Corp. Inv Mgmt Of Virginia Limited Liability Company holds 2.56% or 180,559 shares in its portfolio. Gagnon Limited Liability Corporation has 140,362 shares for 1.8% of their portfolio. Moreover, Macquarie Gp Limited has 0.11% invested in Quidel Corporation (NASDAQ:QDEL). Barclays Public Limited Company holds 24,508 shares. Aristotle Capital Boston Ltd Liability Corporation owns 325,353 shares. Metropolitan Life Insur Ny owns 10,830 shares. Alps Advisors invested in 5,746 shares or 0% of the stock. Royal Savings Bank Of Canada invested 0% in Quidel Corporation (NASDAQ:QDEL). Aqr Cap Limited Liability Co has invested 0% in Quidel Corporation (NASDAQ:QDEL). 5,611 were accumulated by Mackenzie Financial Corp. Principal Fincl Gp accumulated 0% or 21,418 shares. Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Quidel Corporation (NASDAQ:QDEL) for 4,943 shares. 60,741 were accumulated by First Trust Advisors Limited Partnership. Vanguard Gp, a Pennsylvania-based fund reported 3.45M shares.

Oracle Investment Management Inc decreased its stake in Quidel Corp (QDEL) by 6.21% based on its latest 2019Q2 regulatory filing with the SEC. Oracle Investment Management Inc sold 118,294 shares as the company’s stock declined 7.87% . The hedge fund held 1.79M shares of the in vitro & in vivo diagnostic substances company at the end of 2019Q2, valued at $105.90 million, down from 1.90M at the end of the previous reported quarter. Oracle Investment Management Inc who had been investing in Quidel Corp for a number of months, seems to be less bullish one the $2.78B market cap company. The stock decreased 1.84% or $1.26 during the last trading session, reaching $67.16. About 313,070 shares traded or 46.54% up from the average. Quidel Corporation (NASDAQ:QDEL) has declined 9.66% since September 13, 2018 and is downtrending. It has underperformed by 9.66% the S&P500.

Analysts await Quidel Corporation (NASDAQ:QDEL) to report earnings on November, 5. They expect $0.59 earnings per share, up 9.26 % or $0.05 from last year’s $0.54 per share. QDEL’s profit will be $24.45M for 28.46 P/E if the $0.59 EPS becomes a reality. After $0.30 actual earnings per share reported by Quidel Corporation for the previous quarter, Wall Street now forecasts 96.67 % EPS growth.

More notable recent Quidel Corporation (NASDAQ:QDEL) news were published by: which released: “Quidel (QDEL) Presents At 37th Annual J.P. Morgan Healthcare Conference – Slideshow – Seeking Alpha” on January 10, 2019, also with their article: “Here’s Why You Should Retain NextGen Healthcare (NXGN) Stock – Nasdaq” published on June 07, 2019, published: “RSI Alert: Quidel (QDEL) Now Oversold – Nasdaq” on May 14, 2019. More interesting news about Quidel Corporation (NASDAQ:QDEL) were released by: and their article: “5 Small Cap Stocks With Growth AND Value – Nasdaq” published on June 20, 2019 as well as‘s news article titled: “Quidel (QDEL) Q2 2019 Earnings Call Transcript – Yahoo Finance” with publication date: August 08, 2019.

Quidel Corporation (NASDAQ:QDEL) Ratings Coverage

Among 2 analysts covering Quidel (NASDAQ:QDEL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Quidel has $77 highest and $74 lowest target. $75.50’s average target is 12.42% above currents $67.16 stock price. Quidel had 3 analyst reports since March 18, 2019 according to SRatingsIntel. The firm has “Strong Buy” rating given on Monday, April 15 by Raymond James. The company was maintained on Monday, March 18 by Barclays Capital.

Quidel Corporation (NASDAQ:QDEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.